Drugs / NDI-219216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06898450 | Mar 2025 → Oct 2031 expected | — | Nimbus Wadjet, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDI-219216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06898450 ↗ |
| Action | Inhibit | “inhibitor of WRN helicase activity” NCT06898450 ↗ |
| Modality | Small molecule | “highly selective small molecule inhibitor” NCT06898450 ↗ |
| Route | Oral | “Take NDI-219216 every day by mouth.” NCT06898450 ↗ |
| Target | WRN | “inhibitor of WRN helicase activity” NCT06898450 ↗ |